Erytec Pharma : 2021: set to be a decisive year
>TRYbeCA-1: verdict expected in Q4 - At the end of last week, we had the opportunity to review with Erytech’s management the company’s latest developments as well as the main upcoming clinical and regulatory milestones. The publication of the final results of phase III studying eryaspase in 2L pancreatic cancer remains, in our view, the main driver for the stock. At the start of the year, an Independent Data Monitoring Committee (IDMC) had recommended the continuation...Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.